Cambridge biotech TRIMTECH Therapeutics, which is harnessing targeted protein degradation for the treatment of neurodegenerative diseases, has closed an oversubscribed $31 million (£25m) seed round ...
Credit: Art_Photo/Shutterstock. Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of the central nervous system (CNS)-penetrant therapeutics that are based ...
Hosted on MSN16d
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseasesTRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million ...
Headquartered in Cambridge, UK, TRIMTECH is developing TRIMTAC aggregate-selective degrader molecules, designed to selectively eliminate disease-associated protein aggregates while preserving ...
Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of the central nervous system (CNS)-penetrant therapeutics that are based on Trimtacs, the aggregate ...
TRIMTECH is leveraging the innate properties of the E3 ubiquitin ligase TRIM21 to selectively and potently degrade protein aggregates associated with a range of diseases which are not well served by ...
TRIMTECH is leveraging the innate properties of the E3 ubiquitin ligase TRIM21 to selectively and potently degrade protein aggregates associated with a range of diseases which are not well served ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results